Loading...
XSHG
600216
Market cap1.96bUSD
Oct 10, Last price  
14.55CNY
1D
0.62%
1Q
-4.78%
Jan 2017
14.75%
Name

Zhejiang Medicine Co Ltd

Chart & Performance

D1W1MN
P/E
12.06
P/S
1.49
EPS
1.21
Div Yield, %
1.03%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
5.88%
Revenues
9.38b
+20.29%
1,884,658,7272,196,496,6402,208,825,5913,761,029,3284,183,740,7744,558,265,1734,825,968,3785,264,006,1164,932,920,2364,832,291,8324,496,662,3785,279,204,0315,692,580,3656,858,741,5807,043,927,6187,326,934,7999,129,094,4968,115,804,6487,794,145,9719,375,216,922
Net income
1.16b
+170.11%
81,643,17060,618,55656,604,978972,627,3141,213,754,8251,144,708,6941,012,476,289848,542,502452,095,249169,739,354161,801,304450,102,013253,145,602364,549,966342,772,695717,399,5641,045,322,100362,613,741429,639,6261,160,510,670
CFO
1.22b
+92.85%
25,143,347169,506,018227,672,9671,199,977,1811,465,089,3911,316,312,173912,753,822807,488,234655,086,217549,899,398106,539,172336,135,774503,468,945579,907,748447,249,2871,256,721,9801,136,655,957520,603,490634,311,1631,223,298,641
Dividend
Jul 10, 20240.15 CNY/sh

Profile

Zhejiang Medicine Co., Ltd. produces and sells life nutrition and pharmaceutical products in China. The company offers life nutrition products, such as synthetic vitamin E, vitamin A, natural vitamin E, vitamin H, vitamin D3, coenzyme Q10, carotene, cantharidin, lutein, lycopene, and other vitamins and vitamin products. It also provides pharmaceutical manufacturing products, including anti-drug resistant antibiotics, anti-malaria and other pharmaceutical raw materials, quinolones, and anti-drug resistant products; and pharmaceutical products comprising sugars and hormones. The company was founded in 1997 and is headquartered in Shaoxing, China.
URL
https://www.zmc.top/
IPO date
Oct 21, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,375,217
20.29%
7,794,146
-3.96%
8,115,805
-11.10%
Cost of revenue
7,423,225
7,293,036
7,138,750
Unusual Expense (Income)
NOPBT
1,951,992
501,110
977,055
NOPBT Margin
20.82%
6.43%
12.04%
Operating Taxes
192,031
86,485
128,775
Tax Rate
9.84%
17.26%
13.18%
NOPAT
1,759,961
414,626
848,280
Net income
1,160,511
170.11%
429,640
18.48%
362,614
-65.31%
Dividends
(142,577)
(163,995)
(318,492)
Dividend yield
0.94%
1.60%
2.84%
Proceeds from repurchase of equity
(29,002)
(1,293)
BB yield
0.19%
0.01%
Debt
Debt current
270,281
200,223
600,977
Long-term debt
171,439
230,868
201,426
Deferred revenue
104,595
84,158
54,112
Other long-term liabilities
82,197
1
1
Net debt
(1,680,615)
(1,195,147)
(1,082,968)
Cash flow
Cash from operating activities
1,223,299
634,311
520,603
CAPEX
(689,144)
Cash from investing activities
(473,500)
(464,915)
Cash from financing activities
(255,321)
(195,483)
43,914
FCF
991,459
291,849
98,581
Balance
Cash
2,260,728
1,788,337
1,885,371
Long term investments
(138,393)
(162,098)
Excess cash
1,653,575
1,236,532
1,479,580
Stockholders' equity
9,810,750
6,361,113
8,646,938
Invested Capital
9,842,735
9,264,789
8,980,668
ROIC
18.42%
4.54%
9.94%
ROCE
16.98%
4.77%
9.34%
EV
Common stock shares outstanding
959,100
954,755
958,544
Price
15.86
47.81%
10.73
-8.21%
11.69
-31.56%
Market cap
15,211,322
48.48%
10,244,518
-8.57%
11,205,378
-31.54%
EV
13,750,506
9,405,049
10,572,387
EBITDA
2,675,740
1,226,088
1,658,658
EV/EBITDA
5.14
7.67
6.37
Interest
35,365
28,336
33,112
Interest/NOPBT
1.81%
5.65%
3.39%